Business Wire

Large-Scale Body Composition Study Reveals Link between Specific Fat Distributions and Metabolic Diseases

Jaa

Specific patterns of fat distribution are linked to the presence of Coronary Heart Disease (CHD) and Type 2 Diabetes (T2D), according to a new study published in Obesity. 1 AMRA, the international leader in body composition analysis, today announced the results of a body composition study of over 6,000 subjects, stressing the need to measure and investigate several fat compartments in order to understand and develop treatments for multiple metabolic diseases. The new findings go far beyond what can be described by sex, age, lifestyle, BMI, or a single fat compartment, and have the potential to strongly impact how metabolic conditions will be prevented and managed in the future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005616/en/

The Obesity study was co-authored in collaboration between AMRA, Pfizer, Westminster University, Linköping University, and UK Biobank. The 6,000 subjects analyzed are part of the UK Biobank Imaging Study, a major national and international health resource. In 2015, UK Biobank announced that AMRA would perform the automated analysis of MRI images for precise fat and muscle measurements. AMRA has now developed the technique of body composition profiling, which allows for precise analysis of multiple variables to describe the complex associations and interactions between fat distribution, muscle volumes, and metabolic status.

Regardless of normal, overweight, or obese BMI class, AMRA’s body composition profiling of the subjects revealed a number of skewed fat distribution patterns, or phenotypes, that cannot be described when looking at a single fat or muscle measurement. These phenotypes are associated with different metabolic disease profiles: some exhibit no metabolic disease, while others exhibit CHD, T2D, or the co-morbidity of the two. Specifically, higher visceral fat and muscle fat was associated with CHD and T2D (p<0.001) while higher liver fat was associated with T2D (p<0.001) and lower liver fat with CHD (p<0.05). Lower visceral fat and muscle fat was also associated with metabolic health (p<0.001), whereas liver fat was non-significant. Associations remained significant when adjusting for sex, age, BMI, alcohol, smoking, and physical activity.

Dr Olof Dahlqvist Leinhard, senior author of the study, commented, “It has been known for some time that there are fat distributions that are disadvantageous from a health perspective. Today, new techniques provide high accuracy and precision, enabling in-depth analyses of the clinical importance of body composition at a large scale. What’s exciting is that, by using a multivariable approach and an intuitive visualization of body composition, we’ve been able to identify a wide range of body composition profiles that could provide the link to increased risk of metabolic diseases.”

Tommy Johansson, Chief Executive Officer of AMRA, added, “These ground-breaking results allow a glimpse into the future where precision diagnostics will provide the backbone to personalized medicine. By better understanding of muscle and fat volumes, and where fat is located in the body, we hope to help redefine disease risk and suitability for treatment. Our vision is that, in the future, our research and technology will be used to assist in the improved prevention, diagnosis, and treatment of a wide range of diseases.”

Today a quarter of the world’s adults have Metabolic Syndrome – a cluster of factors that increase the risk of several chronic diseases, such as heart disease, cancer, stroke, liver disease and diabetes.2 Obesity, CVD and T2D are growing pandemics and leading causes of early death globally, presenting some of the greatest challenges to patients and healthcare systems worldwide.3,4,5,6

-ENDS-

Study detail

The first 6,021 participants from the UK Biobank imaging sub-study – mean age 62.3±7.5 years, and BMI 26.7±4.4 kg/m2 – were scanned using a 6-minutes MRI protocol providing a water and fat separated volumetric dataset covering neck to knees, and a single slice for proton density fat fraction (PDFF) assessment in the liver. For body composition, acquired image data were analyzed for visceral adipose tissue, abdominal subcutaneous adipose tissue, thigh muscle volume, muscle fat infiltration in the anterior thighs, and liver PDFF. Briefly, the image analysis comprised of (1) image calibration, (2) fusion of image stacks, (3) image segmentation, (4) quantification of fat and muscle volumes7,8,9,10,11 and manual quality control by an analysis engineer.

Diagnosis information was gathered through in-patient electronic healthcare records and via touchscreen questionnaires followed by interviews performed by trained nurses. For CHD and T2D, two matched control groups were stratified matched on (1) sex and age, and (2) sex, age, and BMI. Participants were considered metabolic disease free if they did not report any conditions considered to be serious enough to represent metabolically-focused health concerns (e.g. cardiovascular and metabolic diseases, severe chronic conditions, neurological diseases, and cancers).12

The study was carried out as a collaboration between AMRA medical, Pfizer, Westminster University and Linköping University. Funding support was provided by Pfizer.

About AMRA

AMRA is the first in the world to transform images from a rapid, 6-minute whole body MRI scan into precise, 3D-volumetric fat and muscle measurements. AMRA’s cloud-based analysis service offers precise, automated insights that have far-reaching implications for the pharmaceutical industry, academic R&D and, soon, clinical practice. AMRA was founded in 2010 as a spin-off of the Center for Medical Image Science and Visualization (CMIV), the Department of Biomedical Engineering (IMT) and the Department of Medicine and Health (IMH) at Linköping University, Sweden. For more information, visit www.amramedical.com.

About UK Biobank

UK Biobank is a major national and international health resource with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40–69 years in 2006–2010 from across the country, when they provided lots of information about their health and well-being and donated samples of blood and urine for long-term storage and analysis, including genetic information. The project has permission to follow participants’ health through medical records. UK Biobank has also embarked on a major project to MRI scan the vital internal organs and body composition of 100,000 participants. Over many years, these detailed data will build a powerful resource to help scientists discover why some people develop particular diseases and others do not, and to suggest new ways of preventing and treating them.

1 http://onlinelibrary.wiley.com/doi/10.1002/oby.22210

2 Worldwide Definition of the Metabolic Syndrome, International Diabetes Federation (IDF)

3 Chang S-H, et al. JAMA Surg 2014;149:275–87

4 IDF diabetes atlas. 2015. Available at: http://www.diabetesatlas.org [last accessed 06.10.16]

5 Branca F, et al. The Challenge of Obesity in the WHO European Region and the Strategies for Response: Summary. 2007

6 Klein S, et al. Obesity (Silver Spring) 2011;19:581–7

7 West J, Dahlqvist Leinhard O, Romu T, et al. Feasibility of MR-based Body Composition Analysis in Large Scale Population Studies. PLoS ONE 2016;11(9)

8 Borga M, Thomas EL, Romu T, et al. Validation of a Fast Method for Quantification of Intra-abdominal and Subcutaneous Adipose Tissue for Large Scale Human Studies. NMR Biomed 2015;28(12):1747–53

9 OD Leinhard, A Johansson, J Rydell, et al. Quantitative Abdominal Fat Estimation Using MRI Pattern Recognition. In: Proceedings of the 19th International Conference on Pattern Recognition (ICPR) 08–11 Dec, 2008; Tampa, FL

10 Karlsson A, Rosander J, Romu T, et al. Automatic and Quantitative Assessment of Regional Muscle Volume by Multi-Atlas Segmentation Using Whole-Body Water-Fat MRI. JMRI 2015;41(6):1558–69

11 West J, Romu T, Thorell S, et al.. Precision of MRI-based body composition measurements of postmenopausal women. PLoS One 2018;13(2):e0192495

12 UK Biobank Data Showcase. Available at: http://biobank.ctsu.ox.ac.uk/crystal/ [last accessed 16.11.17]

Contact information

AMRA Medical AB
Chelsea Ranger
SVP Commercial & Market Strategy
chelsea.ranger@amramedical.com
or
UK Biobank
Andrew Trehearne
Head of Communications
andrew.trehearne@ukbiobank.ac.uk

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45Tiedote

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme